TYRA
Tyra Biosciences Inc.
Company Overview
| Mkt Cap | $815.53M | Price | $35.06 |
| Volume | 801.07K | Change | -5.04% |
| P/E Ratio | -9.4 | Open | $37.00 |
| Revenue | -- | Prev Close | $36.92 |
| Net Income | $-86.5M | 52W Range | $7.80 - $40.65 |
| Div Yield | N/A | Target | $51.24 |
| Overall | 54 | Value | 60 |
| Quality | 31 | Technical | 72 |
No chart data available
About Tyra Biosciences Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest News
Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch
Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch
Tyra Bioscience (TYRA) Gets a Buy from Barclays
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TYRA | $35.06 | -5.0% | 801.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |